Pharsight

Purdue Pharma Lp patents expiration

1. Adhansia Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9974752 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10512612 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10292939 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10500162 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10688060 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10512613 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10292938 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10507186 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10111839 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10449159 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10568841 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(11 years from now)

US10722473 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Nov, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-82) Jun 28, 2024
New Product(NP) Feb 27, 2022

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

ADHANSIA XR family patents

Family Patents

2. Butrans patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6344211 PURDUE PHARMA LP Transdermal absorption of active substances from subcooled melts
Dec, 2015

(8 years ago)

US6264980 PURDUE PHARMA LP Transdermal resorption of active substances from supercooled masses of levulic acid
Dec, 2015

(8 years ago)

USRE41408 PURDUE PHARMA LP Method of providing sustained analgesia with buprenorpine
Sep, 2017

(6 years ago)

US9642850 PURDUE PHARMA LP Method of providing sustained analgesia with buprenorphine
Sep, 2017

(6 years ago)

USRE41571 PURDUE PHARMA LP Method of providing sustained analgesia with buprenorphine
Sep, 2017

(6 years ago)

USRE41489 PURDUE PHARMA LP Method of providing sustained analgesia with buprenorphine
Sep, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-250) Oct 13, 2020
New Dosage Form(NDF) Jun 30, 2013

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 30 June, 2010

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; The management of moderate to severe chronic...

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of BUTRANS before it's drug patent expiration?
More Information on Dosage

BUTRANS family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Chirocaine patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5708011 PURDUE PHARMA LP Use of levobupivacaine in a patient having depressed myocardial contractility
Oct, 2014

(9 years ago)

Drugs and Companies using LEVOBUPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 August, 1999

Treatment: Method of use of levobupivacaine

Dosage: INJECTABLE;INJECTION

More Information on Dosage

CHIROCAINE family patents

Family Patents

4. Hysingla Er patents expiration

HYSINGLA ER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6488963 PURDUE PHARMA LP Hot-melt extrudable pharmaceutical formulation
Jun, 2017

(6 years ago)

US9060940 PURDUE PHARMA LP Controlled release hydrocodone
Oct, 2020

(3 years ago)

US9517236 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2020

(3 years ago)

US9198863 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2020

(3 years ago)

US9572804 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2020

(3 years ago)

US9056052 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2020

(3 years ago)

US9289391 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2020

(3 years ago)

US9669023 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2020

(3 years ago)

US9682077 PURDUE PHARMA LP Methods of providing analgesia
Oct, 2020

(3 years ago)

US9675611 PURDUE PHARMA LP Methods of providing analgesia
Oct, 2020

(3 years ago)

US9669024 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2020

(3 years ago)

US9023401 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2020

(3 years ago)

US9205056 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2020

(3 years ago)

US6733783 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2021

(2 years ago)

US8551520 PURDUE PHARMA LP Controlled release hydrocodone
Oct, 2021

(2 years ago)

US8361499 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2021

(2 years ago)

US8647667 PURDUE PHARMA LP Controlled release hydrocodone formulations
Oct, 2021

(2 years ago)

US8529948 PURDUE PHARMA LP Pharmaceutical formulation containing gelling agent
Aug, 2022

(1 year, 9 months ago)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(11 months ago)

US9675610 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(11 months ago)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(6 months ago)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(6 months ago)

US11844865 PURDUE PHARMA LP Abuse-proofed oral dosage form
Feb, 2025

(8 months from now)

US9095615 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9775809 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9084816 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US11304908 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9486413 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9095614 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9545380 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9492390 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US11304909 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9486412 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9872837 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(7 years from now)

US9861584 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(7 years from now)

US9750703 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(7 years from now)

US9572779 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(7 years from now)

US8808740 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(7 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HYSINGLA ER before it's drug patent expiration?
More Information on Dosage

HYSINGLA ER family patents

Family Patents

5. Oxycontin patents expiration

OXYCONTIN's oppositions filed in EPO
OXYCONTIN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(10 months from now)

US10407434 PURDUE PHARMA LP Process for preparing oxycodone compositions
Mar, 2025

(10 months from now)

US10696684 PURDUE PHARMA LP Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(10 months from now)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5508042 PURDUE PHARMA LP Controlled release oxycodone compositions
Apr, 2013

(11 years ago)

US6488963 PURDUE PHARMA LP Hot-melt extrudable pharmaceutical formulation
Jun, 2017

(6 years ago)

US9060976 PURDUE PHARMA LP Pharmaceutical formulation containing gelling agent
Aug, 2022

(1 year, 9 months ago)

US8337888 PURDUE PHARMA LP Pharmaceutical formulation containing gelling agent
Aug, 2022

(1 year, 9 months ago)

US9675610 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(11 months ago)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(11 months ago)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(6 months ago)

US10675278 PURDUE PHARMA LP Crush resistant delayed-release dosage forms
Nov, 2023

(6 months ago)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(6 months ago)

US8114383 PURDUE PHARMA LP Abuse-proofed dosage form
Oct, 2024

(4 months from now)

US7674800 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(10 months from now)

US7674799 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(10 months from now)

US7683072 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(10 months from now)

US7776314 PURDUE PHARMA LP Abuse-proofed dosage system
Apr, 2025

(10 months from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US8894988 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US8808741 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9492393 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US11304909 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9492392 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9775808 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US11304908 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US8894987 PURDUE PHARMA LP Tamper resistant dosage forms
Mar, 2030

(5 years from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 12 December, 1995

Treatment: Management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time; Management of pain severe enough to require daily, around-the-clock, long ...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

OXYCONTIN family patents

Family Patents

6. Palladone patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5965161 PURDUE PHARMA LP Extruded multi-particulates
Nov, 2014

(9 years ago)

US6706281 PURDUE PHARMA LP Melt-extrusion multiparticulates
Nov, 2014

(9 years ago)

US6335033 PURDUE PHARMA LP Melt-extrusion multiparticulates
Nov, 2014

(9 years ago)

US6743442 PURDUE PHARMA LP Melt-extruded orally administrable opioid formulations
Nov, 2014

(9 years ago)

US5958452 PURDUE PHARMA LP Extruded orally administrable opioid formulations
Nov, 2014

(9 years ago)

US6589960 PURDUE PHARMA LP Hydromorphone and hydrocodone compositions and methods for their synthesis
Nov, 2020

(3 years ago)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 September, 2004

Treatment: Management of persistent, moderate to severe pain in patients requiring continuous, around-the-clock analgesia with a high potency opioid for an extended period of time generally weeks to months or lo...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

PALLADONE family patents

Family Patents

7. Targiniq patents expiration

TARGINIQ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7683072 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(10 months from now)

US7674800 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(10 months from now)

US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(10 months from now)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474750 PURDUE PHARMA LP Opioid agonist/opioid antagonist/acetaminophen combinations
Dec, 2018

(5 years ago)

US6277384 PURDUE PHARMA LP Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

US8822487 PURDUE PHARMA LP Opioid agonist/opioid antagonist/acetaminophen combinations
Dec, 2018

(5 years ago)

US9205082 PURDUE PHARMA LP Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

US8673355 PURDUE PHARMA LP Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

US6696066 PURDUE PHARMA LP Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

US9084729 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9056051 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9283216 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9511066 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9161937 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9345701 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9168252 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US8969369 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9283221 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9555000 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(1 year, 1 month ago)

US8846090 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(1 year, 1 month ago)

US9907793 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(1 year, 1 month ago)

US8846091 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(1 year, 1 month ago)

US7674799 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(10 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jul 23, 2017

Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 July, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

TARGINIQ family patents

Family Patents